Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P134
- Development stage
- Unknown
- Lead developer
- Tasly Pharmaceutical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumoral, Intraventricular
01
Overview
P134 is an innovative autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target both CD44 and CD133 antigens. Developed by Tasly Pharmaceutical Group in collaboration with the Beijing Neurosurgical Institute and Beijing Tiantan Hospital, it is specifically indicated for the treatment of recurrent glioblastoma (GBM), including IDH wild-type cases. The therapy's dual-targeting mechanism aims to overcome tumor heterogeneity by recognizing antigens that are highly and mutually exclusively expressed in primary and recurrent GBM. By binding to these targets, P134 cells are activated to eliminate tumor cells and exhibit prolonged T-cell lifespan. It is currently being evaluated in Phase 1/2 clinical trials using intratumoral or intraventricular administration via an Ommaya reservoir.
- Other names
- P134 Cell InjectionP-134 Cell InjectionP 134 Cell InjectionCD44/CD133 dual-targeting CAR-T cells
02
Targets
CD133 (CD133 antigen)CD44 (CD44 antigen)
Beyond the preview
Go deeper on P134.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P134.